Edward Nash
Stock Analyst at Canaccord Genuity
(3.90)
# 648
Out of 5,241 analysts
83
Total ratings
50%
Success rate
11.22%
Average return
Main Sectors:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $587 → $578 | $523.69 | +10.37% | 13 | May 7, 2026 | |
| KYMR Kymera Therapeutics | Initiates: Buy | $106 | $82.21 | +28.94% | 1 | May 6, 2026 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 → $49 | $6.90 | +610.14% | 3 | May 4, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $62 → $64 | $56.51 | +13.25% | 2 | Apr 29, 2026 | |
| GPCR Structure Therapeutics | Initiates: Buy | $101 | $38.69 | +161.05% | 1 | Apr 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Buy | $47 → $56 | $42.59 | +31.49% | 11 | Apr 14, 2026 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $8 | $1.32 | +506.06% | 4 | Apr 6, 2026 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 → $5 | $1.08 | +362.96% | 3 | Apr 1, 2026 | |
| CORT Corcept Therapeutics | Maintains: Buy | $100 → $110 | $56.37 | +95.14% | 13 | Mar 26, 2026 | |
| APGE Apogee Therapeutics | Maintains: Buy | $89 → $130 | $81.14 | +60.22% | 2 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4 → $3 | $1.15 | +160.87% | 3 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.11 | +1,084.83% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $107 | $30.27 | +253.49% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $5.44 | +267.65% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 | $31.34 | +97.83% | 3 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.34 | +408.98% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $4.64 | -56.90% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $0.60 | +29,900.00% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $52 | $10.28 | +405.84% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $25.00 | +228.00% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $27.05 | +77.45% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.49 | +11,739.71% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
May 7, 2026
Maintains: Buy
Price Target: $587 → $578
Current: $523.69
Upside: +10.37%
Kymera Therapeutics
May 6, 2026
Initiates: Buy
Price Target: $106
Current: $82.21
Upside: +28.94%
Sagimet Biosciences
May 4, 2026
Maintains: Buy
Price Target: $28 → $49
Current: $6.90
Upside: +610.14%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintains: Buy
Price Target: $62 → $64
Current: $56.51
Upside: +13.25%
Structure Therapeutics
Apr 27, 2026
Initiates: Buy
Price Target: $101
Current: $38.69
Upside: +161.05%
Travere Therapeutics
Apr 14, 2026
Maintains: Buy
Price Target: $47 → $56
Current: $42.59
Upside: +31.49%
Cardiol Therapeutics
Apr 6, 2026
Maintains: Buy
Price Target: $8
Current: $1.32
Upside: +506.06%
Rani Therapeutics Holdings
Apr 1, 2026
Maintains: Buy
Price Target: $9 → $5
Current: $1.08
Upside: +362.96%
Corcept Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $100 → $110
Current: $56.37
Upside: +95.14%
Apogee Therapeutics
Mar 24, 2026
Maintains: Buy
Price Target: $89 → $130
Current: $81.14
Upside: +60.22%
Mar 13, 2026
Maintains: Hold
Price Target: $4 → $3
Current: $1.15
Upside: +160.87%
Dec 18, 2025
Initiates: Buy
Price Target: $25
Current: $2.11
Upside: +1,084.83%
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $30.27
Upside: +253.49%
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $5.44
Upside: +267.65%
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $31.34
Upside: +97.83%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.34
Upside: +408.98%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $4.64
Upside: -56.90%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $0.60
Upside: +29,900.00%
Aug 5, 2022
Downgrades: Hold
Price Target: $52
Current: $10.28
Upside: +405.84%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $25.00
Upside: +228.00%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $27.05
Upside: +77.45%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.49
Upside: +11,739.71%